Paula Ragan - Feb 12, 2024 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Role
President and CEO, Director
Signature
/s/ Adam S. Mostafa, attorney-in-fact
Stock symbol
XFOR
Transactions as of
Feb 12, 2024
Transactions value $
-$21,892
Form type
4
Date filed
2/12/2024, 05:05 PM
Previous filing
Nov 3, 2023
Next filing
Feb 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XFOR Common Stock Sale -$21.9K -21.7K -2.59% $1.01 815K Feb 12, 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 24, 2023.
F2 Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $0.97 to $1.05, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.